Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01068860
Registration number
NCT01068860
Ethics application status
Date submitted
12/02/2010
Date registered
15/02/2010
Date last updated
5/09/2011
Titles & IDs
Public title
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
Query!
Scientific title
A Multi-center, Double-blind, Placebo-controlled, Randomized Study to Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes Treated With Differing Baseline Diabetes Therapies
Query!
Secondary ID [1]
0
0
CACZ885I2207
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Type 2 Diabetes Mellitus
0
0
Query!
Impaired Glucose Tolerance
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Metabolic disorders
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Other metabolic disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Canakinumab 150 mg
Treatment: Drugs - Placebo to Canakinumab
Experimental: Canakinumab 150 mg + Metformin - Eligible participants received a single subcutaneous injection Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
Placebo Comparator: Placebo + Metformin - Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
Experimental: Canakinumab 150 mg + Metforimin + Sulfonylurea - Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
Placebo Comparator: Placebo + Metforimin + Sulfonylurea - Eligible participants received a single subcutaneous injection of Placebo to Canakinumab.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
Experimental: Canakinumab 150 mg + Met + Sulfonyl + Thiazolidinedione - Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
Placebo Comparator: Placebo + Met + Sulfonyl + Thiazolidinedione - Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
Experimental: Canakinumab 150 mg + Insulin - Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
Placebo Comparator: Placebo + Insulin - Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
Experimental: Canakinumab 150 mg in patients with IGT - Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
Placebo Comparator: Placebo in patients with IGT - Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
Treatment: Drugs: Canakinumab 150 mg
Single subcutaneous injection of Canakinumab 150 mg.
Treatment: Drugs: Placebo to Canakinumab
Single subcutaneous injection of Placebo to Canakinumab.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-2 Hours, From Baseline to 4 Weeks.
Query!
Assessment method [1]
0
0
Change in Insulin Secretion Rate stimulated by Liquid mixed-meal challenge. Blood samples were taken prior to and after meal for glucose and insulin at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes relative to the start of the meal.A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include patients from the IGT population
Query!
Timepoint [1]
0
0
Baseline, 4 weeks
Query!
Secondary outcome [1]
0
0
Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 2-4 Hours, From Baseline to 4 Weeks
Query!
Assessment method [1]
0
0
Change in Insulin Secretion Rate stimulated by Liquid mixed-meal challenge Blood samples were taken prior to and after meal for glucose and insulin at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes relative to the start of the meal. A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population
Query!
Timepoint [1]
0
0
Baseline, 4 weeks
Query!
Secondary outcome [2]
0
0
Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-4 Hours, From Baseline to 4 Weeks.
Query!
Assessment method [2]
0
0
Change in Insulin Secretion Rate stimulated by Liquid mixed-meal challenge. Blood samples were taken prior to and after meal for glucose, insulin and C-peptide at sample times: -20, -10, -1 and 10, 20, 30, 60, 90, 120, 180, and 240 minutes relative to the start of the meal. A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population.
Query!
Timepoint [2]
0
0
Baseline, 4 weeks
Query!
Secondary outcome [3]
0
0
Mean Change in Fasting Plasma Glucose, From Baseline to 4 Weeks
Query!
Assessment method [3]
0
0
Change in Fasting Glucose Level measured from plasma taken at Baseline and after 4 weeks of treatment.
A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population
Query!
Timepoint [3]
0
0
Baseline, 4 weeks
Query!
Secondary outcome [4]
0
0
Mean Change in Fructosamine, From Baseline to 4 Weeks
Query!
Assessment method [4]
0
0
Change in Fructosamine Level taken from plasma, measured at Baseline and after 4 weeks of treatment.
A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population
Query!
Timepoint [4]
0
0
Baseline, 4 weeks
Query!
Secondary outcome [5]
0
0
Mean Change in Fasting Plasma Insulin, From Baseline to 4 Weeks
Query!
Assessment method [5]
0
0
Change in Fasting Insulin level taken from plasma, measured at Baseline and after 4 weeks of treatment.
A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population
Query!
Timepoint [5]
0
0
Baseline, 4 weeks
Query!
Secondary outcome [6]
0
0
Mean Change in Quantitative Insulin Sensitivity Check Index (QUICKI) Score, From Baseline to 4 Weeks
Query!
Assessment method [6]
0
0
The Quantitative Insulin Sensitivity Check Index (QUICKI) score, measures insulin sensitivity which is the inverse of insulin resistance. The score is calculated by the equation: 1 /(log(fasting insulin µU/mL) + log(fasting glucose mg/dL)). In normal subjects the mean score ± SE is 0.366 ± 0.029.
A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population.
Query!
Timepoint [6]
0
0
Baseline, 4 weeks
Query!
Secondary outcome [7]
0
0
Mean Change in Fasting Glucose Disposition Index(GDI)1 and Index 2, From Baseline to 4 Weeks
Query!
Assessment method [7]
0
0
GDI 1 is the product of insulin sensitivity index (Si)during the 1st phase of insulin secretion and ß-cell function as measured by the acute insulin response (AIR).GDI 2 is the product of (Si)during the 2nd phase of insulin secretion and ß-cell function as measured by the acute insulin response (AIR). A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT group.
Query!
Timepoint [7]
0
0
Baseline, 4 weeks
Query!
Secondary outcome [8]
0
0
Mean Change in Absolute Glucose Level at 2 Hours, From Baseline to 4 Weeks
Query!
Assessment method [8]
0
0
Change in glucose level measured after 2 hours of fasting. Blood sample was drawn at 0 minutes and at 240 minutes.
A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population.
Query!
Timepoint [8]
0
0
Baseline, 4 weeks
Query!
Secondary outcome [9]
0
0
Mean Change in Insulin Area Under the Curve (AUC) 0-4 Hours, From Baseline to 4 Weeks
Query!
Assessment method [9]
0
0
Blood samples were drawn after a test meal at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve,(AUC). AUC was calculated as: x=1 AUC SAx n Where Ax = AUC for the 240 min.interval, and X = 1 for the 1st interval. A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab vs placebo within each T2DM group. The mixed model didn't include the IGT group.
Query!
Timepoint [9]
0
0
Baseline, 4 weeks
Query!
Secondary outcome [10]
0
0
Mean Change in C-peptide Area Under the Curve (AUC), 0-4 Hours, From Baseline to 4 Weeks
Query!
Assessment method [10]
0
0
Blood samples were drawn after a test meal at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve,(AUC). AUC was calculated as: x=1 AUC SAx n Where Ax = AUC for the 240 min.interval, and X = 1 for the 1st interval. A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab vs placebo within each T2DM group. The mixed model didn't include the IGT group.
Query!
Timepoint [10]
0
0
Baseline, 4 weeks
Query!
Secondary outcome [11]
0
0
Mean Change in Post-prandial Glucose Area Under the Curve (AUC)0-4 Hours, From Baseline to 4 Weeks
Query!
Assessment method [11]
0
0
Blood samples were drawn after a test meal at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. Insulin levels over 4 hrs were shown as Area Under the Curve,(AUC). AUC was calculated as: x=1 AUC SAx n Where Ax = AUC for the 240 min.interval, and X = 1 for the 1st interval. A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab vs placebo within each T2DM group. The mixed model didn't include the IGT group.
Query!
Timepoint [11]
0
0
Baseline, 4 weeks
Query!
Secondary outcome [12]
0
0
Mean Change in Peak Plasma Glucose, From Baseline to 4 Weeks
Query!
Assessment method [12]
0
0
Change in peak plasma glucose level as measured from Baseline to 4 weeks of treatment.
A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population.
Query!
Timepoint [12]
0
0
Baseline, 4 weeks
Query!
Secondary outcome [13]
0
0
Mean Change in Peak Plasma Insulin, From Baseline to 4 Weeks
Query!
Assessment method [13]
0
0
Change in mean peak plasma Insulin level as measured from Baseline to 4 weeks of treatment. A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population.
Query!
Timepoint [13]
0
0
Baseline, 4 weeks
Query!
Secondary outcome [14]
0
0
Mean Change in Peak Plasma C-peptide Level, From Baseline to 4 Weeks
Query!
Assessment method [14]
0
0
Change in mean peak plasma C-peptide level measured from Baseline to 4 weeks of treatment.
A mixed model with treatment fitted as fixed effect, and population and the interaction of population and treatment fitted as random effects were used for the comparison of Canakinumab versus placebo within each T2DM population. The mixed model did not include participants from the IGT population.
Query!
Timepoint [14]
0
0
Baseline, 4 weeks
Query!
Secondary outcome [15]
0
0
Number of Participants Reporting Death, Serious Adverse Events (SAEs) and Adverse Events (AEs) Above 5% Frequency, From Baseline to 4 Weeks
Query!
Assessment method [15]
0
0
An adverse event is any unwanted event, whether related to study drug or not occuring during the study period. A Serious Adverse Event (SAE) is an event resulting in death, requiring or prolonging hospitalization, a congenital anomaly or other important medical event. AEs and SAEs were recorded at each visit.
Query!
Timepoint [15]
0
0
Baseline, 4 weeks
Query!
Eligibility
Key inclusion criteria
1. Patient must fulfill all criteria in one of the following groups:
- Impaired Glucose Tolerance (IGT) as diagnosed per protocol and not on an
anti-diabetic medicine during the study
- Diagnosis of Type 2 diabetes in stable treatment with metformin
- Diagnosis of Type 2 diabetes in stable treatment with metformin (at least 1000
mg/day) in combination with a sulfonylurea
- Diagnosis of Type 2 diabetes in stable treatment with metformin (at least 1000
mg/day), sulfonylurea and thiazolidinedione combination therapy
- Diagnosis of Type 2 diabetes in stable treatment with at least two insulin
injections a day with or without metformin
2. HbA1c between 6.5% and 8%, inclusive, at Screening; this criterion does not apply to
the IGT group
3. Age from 18-74 years, inclusive, and of either sex
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
74
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Type 1 diabetes or diabetes that is a result of pancreatic injury or other secondary
forms of diabetes
2. History or current findings of active pulmonary disease (e.g. tuberculosis, fungal
diseases) as defined in the protocol:
3. Known presence or suspicion of active or recurrent bacterial, fungal or viral
infection at the time of enrollment proven.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/08/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
246
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Barwon Health - Geelong Hospital - Geelong
Query!
Recruitment hospital [2]
0
0
Austin Health - Heidelberg Repatriation Hospital - Heidelberg Heights
Query!
Recruitment hospital [3]
0
0
Melbourne Health - Royal Melbourne Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Geelong
Query!
Recruitment postcode(s) [2]
0
0
- Heidelberg Heights
Query!
Recruitment postcode(s) [3]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Kentucky
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Nebraska
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
North Dakota
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Pennsylvania
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Texas
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Utah
Query!
Country [8]
0
0
Canada
Query!
State/province [8]
0
0
Ontario
Query!
Country [9]
0
0
Canada
Query!
State/province [9]
0
0
Quebec
Query!
Country [10]
0
0
Finland
Query!
State/province [10]
0
0
Helsinki
Query!
Country [11]
0
0
Finland
Query!
State/province [11]
0
0
Oulu
Query!
Country [12]
0
0
Germany
Query!
State/province [12]
0
0
Berlin
Query!
Country [13]
0
0
Germany
Query!
State/province [13]
0
0
Duesseldorf
Query!
Country [14]
0
0
Germany
Query!
State/province [14]
0
0
Duisburg
Query!
Country [15]
0
0
Germany
Query!
State/province [15]
0
0
Essen
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Falkensee
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Hildesheim
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Karlsruhe
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Luebeck
Query!
Country [20]
0
0
Germany
Query!
State/province [20]
0
0
Muenster
Query!
Country [21]
0
0
Germany
Query!
State/province [21]
0
0
Neumuenster
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Potsdam
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Viernheim
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Wetzlar-Naunheim
Query!
Country [25]
0
0
India
Query!
State/province [25]
0
0
AP
Query!
Country [26]
0
0
India
Query!
State/province [26]
0
0
Kar
Query!
Country [27]
0
0
India
Query!
State/province [27]
0
0
KAR
Query!
Country [28]
0
0
India
Query!
State/province [28]
0
0
Ker
Query!
Country [29]
0
0
India
Query!
State/province [29]
0
0
Maharastra
Query!
Country [30]
0
0
India
Query!
State/province [30]
0
0
Mah
Query!
Country [31]
0
0
India
Query!
State/province [31]
0
0
MP
Query!
Country [32]
0
0
India
Query!
State/province [32]
0
0
TN
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
BG
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
GE
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
MI
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Mi
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
PV
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
SI
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
To
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Roma
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This was a 10-week, placebo-controlled, randomized study to investigate the effect of
injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or
Type 2 Diabetes Mellitus (T2DM) already treated on different background diabetes therapies.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01068860
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals Corporation
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01068860
Download to PDF